Cognition Therapeutics/$CGTX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Cognition Therapeutics
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).
- Ticker
- $CGTX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 14
- Headquarters
- Purchase, United States
- Website
- www.cogrx.com
CGTX Metrics
BasicAdvanced
$64M
-
-$0.18
-
-
Price and volume
Market cap
$64M
52-week high
$1.81
52-week low
$0.55
Average daily volume
543K
Financial strength
Current ratio
6.677
Quick ratio
6.486
Long term debt to equity
0.014
Total debt to equity
0.017
Interest coverage (TTM)
-2,685.93%
Profitability
EBITDA (TTM)
-37.557
Management effectiveness
Return on assets (TTM)
-60.11%
Return on equity (TTM)
-48.60%
Valuation
Price to book
2.2
Price to tangible book (TTM)
2.2
Price to free cash flow (TTM)
-4.021
Free cash flow yield (TTM)
-24.87%
Free cash flow per share (TTM)
-0.168
Growth
Earnings per share change (TTM)
-61.37%
3-year earnings per share growth (CAGR)
-39.47%
What the Analysts think about CGTX
Analyst ratings (Buy, Hold, Sell) for Cognition Therapeutics stock.
Analyst projections of the future price of Cognition Therapeutics stock.
CGTX Financial Performance
Revenues and expenses
CGTX Earnings Performance
Company profitability
Upcoming events
No upcoming events
CGTX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.